The best choice depends on the reason for treatment and the evidence for the specific medicine. Studies of GLP-1 drugs and heart attacks include several different populations. This review focused on people with type 2 diabetes and a history of heart attack [1].
What the comparison found
Against placebo, the hazard ratio for major cardiovascular events was 0.87 for SGLT2 inhibitors and 0.83 for GLP-1 drugs. The indirect comparison of SGLT2 inhibitors with GLP-1s gave 1.05 (95% CI 0.92 to 1.20) [1]. It did not establish a clear advantage for either class.
For heart failure admission, the indirect hazard ratio was 0.83 (95% CI 0.67 to 1.03). The estimate favored SGLT2 inhibitors, but the interval included no difference. Most studies included people whose heart attacks occurred well before enrollment. The findings are less directly applicable immediately after a heart attack.
How clinicians choose between the classes
The 2026 ADA and EASD consensus uses a person’s cardiovascular and kidney risk to guide treatment [2]. Our guide to taking a GLP-1 and an SGLT2 inhibitor together covers a third option clinicians may consider. The indirect class comparison above estimates outcomes for each class separately.
Heart failure, chronic kidney disease, weight goals and tolerability all affect that choice.